Is Sentinel Lymph Node Biopsy Still Needed in Early-Stage Breast Cancer?

A New Look at a Longstanding Surgery

For decades, sentinel lymph node biopsy (SLNB) has been a routine part of breast cancer surgery. This procedure removes a few lymph nodes from the armpit to check if cancer has spread beyond the breast. It replaced full axillary node dissection for most women and reduced complications like lymphedema.

But now, new research is asking an important question:

Do all women with early-stage breast cancer still need this surgery?

What Is a Sentinel Lymph Node Biopsy?

A sentinel lymph node biopsy identifies and removes the first few lymph nodes that drain from the breast. If these “sentinel” nodes are free of cancer, additional lymph nodes are not removed.

Even though SLNB is far less invasive than the older full axillary dissection, it can still lead to temporary or long-term side effects such as swelling, stiffness, and discomfort. Researchers are exploring whether some women might safely avoid even this smaller surgery.

Landmark Studies: INSEMA and SOUND

Two large studies, INSEMA and SOUND, recently published in The New England Journal of Medicine and JAMA Oncology, examined whether some women could safely skip SLNB.

Who was studied?

• Women with early-stage breast cancer (mostly T1 tumors ≤ 2 cm)
• Clinically negative lymph nodes confirmed by ultrasound
• Most had hormone receptor-positive, HER2-negative cancers
• All were having breast-conserving surgery

What did the studies find?

• Skipping SLNB did not worsen survival
• Axillary recurrence was very low:
  • SOUND: less than 1%
  • INSEMA: about 1%
• Most women avoided additional surgery without harming outcomes

Who Might Still Benefit from SLNB?

While these results are exciting, the studies included very few women with higher-risk features:

• T2 tumors (>2 cm)
• High-grade (grade 3) cancers
• HER2-positive or triple-negative breast cancer

In INSEMA, 21% of T2 tumors had positive lymph nodes, nearly double that of T1 tumors. This suggests that for larger or more aggressive cancers, skipping SLNB might not be safe.

Why These Findings Matter Beyond Surgery

The decision to omit SLNB affects more than just the operation:

• Radiation Planning:
  Some women are eligible for partial-breast radiation only if lymph nodes are proven negative. Skipping SLNB might mean full-breast radiation is recommended.
• Systemic Treatment:
  Certain treatments (like CDK4/6 inhibitors such as abemaciclib or ribociclib) were studied primarily in patients with node-positive disease. If SLNB is skipped, there may be uncertainty about eligibility.
• Shared Decision-Making:
  These studies highlight the growing trend of personalized treatment decisions. Some women will choose less surgery, while others may want more certainty.

So, Who Might Skip SLNB?

Experts suggest that ideal candidates for omitting SLNB may be:

• Postmenopausal
• Have small (≤2 cm), low-grade (1 or 2) tumors
• Hormone receptor–positive and HER2-negative
• Clinically node-negative on a high-quality axillary ultrasound

Key Takeaway

Sentinel lymph node biopsy is no longer considered a “one size fits all” procedure. For some women with very low-risk breast cancers, skipping this surgery may be safe, but it’s not right for everyone.

Every decision should be made together with your breast surgeon and oncology team, considering your tumor size, grade, imaging, and overall treatment plan.

Frequently Asked Questions About Sentinel Lymph Node Biopsy

Q1: What are the side effects of a sentinel lymph node biopsy?
A: Common short-term side effects include swelling, bruising, and tenderness under the arm. Long-term risks can include arm stiffness, numbness, and, rarely, lymphedema.

Q2: If I skip a sentinel node biopsy, how will doctors know if my cancer has spread?
A: Doctors will rely on clinical exams and imaging, particularly high-quality ultrasound. The INSEMA and SOUND trials showed that in carefully selected patients, this approach can be safe.

Q3: Does skipping SLNB mean I won’t need radiation therapy?
A: Not necessarily. In fact, skipping SLNB can sometimes mean you will receive a broader field of radiation rather than partial-breast treatment, because doctors cannot confirm node-negative status.

Q4: Could skipping SLNB affect my chances of getting certain treatments?
A: Yes. Some newer treatments are approved for use in patients with node-positive disease. Without node testing, eligibility for these drugs may be uncertain.

Q5: Are there new guidelines yet on skipping SLNB?
A: Formal guidelines are evolving as these trial results are reviewed. Talk to your doctor about whether your specific cancer type and stage make you a candidate.

A Final Word from Learn Look Locate

This blog has been medically reviewed and vetted by Dr. Charles Weaver, Medical Oncologist and Learn Look Locate Medical Advisor.
Our mission is to ensure that every patient has access to the latest, medically accurate information in a way that feels supportive and easy to understand.